echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Novo Nordisk's "once a week" new diabetes drug is officially approved in China

    Novo Nordisk's "once a week" new diabetes drug is officially approved in China

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 29, Novo Nordisk issued a press release stating that the National Medical Products Administration (NMPA) has approved Novo Nordisk's research and development and production of Novotel® (Smeglutide Injection) in China for the listing application.

    Novotel® (Smeglutide Injection) is a new long-acting glucagon-like peptide-1 (GLP-1) analogue of Novo Nordisk.
    It is currently available in the United States, Europe, Canada, and Japan.
    Approved for listing in 52 countries and regions.

    Novotel® has a half-life of 7 days and is suitable for once a week injection with a stable blood concentration.
    The SUSTAIN series of studies have shown that Novotel® can significantly reduce glycated hemoglobin (HbA1c), no matter whether it is used as a single agent or combined with other oral hypoglycemic drugs or basal insulin, with a maximum reduction of 1.
    8%.
    The hypoglycemic effect is significantly better than that of placebo and western medicine.
    Gliptin, canagliflozin, dulaglutide, liraglutide, exenatide weekly preparations and insulin glargine and other hypoglycemic drugs.
    In clinical studies registered in China, Nuovotai® has an HbA1c compliance rate of 86.
    1% in the Chinese population, showing a good hypoglycemic effect.
    At the same time, the SUSTAIN 6 study shows that Novotel® can significantly reduce the risk of MACE in patients with type 2 diabetes by 26%, and can significantly improve patients' weight, blood pressure, blood lipids and other indicators, bringing comprehensive benefits for patients with cardiovascular metabolism.

    In January 2020, Novotel® cardiovascular indications were approved by the US FDA to reduce the risk of major cardiovascular events in adult patients with type 2 diabetes with cardiovascular disease.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.